Improving Treatment for IPF
Trial Objectives
Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available.
Who Can Participate
Adults 40 years of age and older.
Age: 40+ Gender: Any
Estimated Time Commitment
Not Specified
Time Commitment Details
Visits will take two to four hours.
Payment & Reimbursement
Payment: Not Provided
Travel Reimbursement: Not Available
Trial Contact
For more information, contact:
Kaitlin Fier
303.270.2852
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
National Institutes of Health
Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit.
Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study.
Principal Investigators
Gregory P. Downey, MD, FRCPC
Co-Investigators
Kevin K. Brown, MD
Request more Information
By completing this form, you agree to learn more about this study and see if you qualify.